Costs and consequences of botulinum toxin type A use: Management of children with cerebral palsy in Germany

被引：15

作者：

Ruiz F.J. ^{[1
]}

Guest J.F. ^{[1
]}

Lehmann A. ^{[1
]}

Davie A.M. ^{[1
]}

Güttler K. ^{[1
]}

Schlüter O. ^{[1
]}

Dreiss G. ^{[2
]}

机构：

[1] Catalyst Hlth. Economics Consultants, Northwood, Middlesex

[2] DRK Krankenhaus Seepark, Debstedt

来源：

The European Journal of Health Economics, formerly: HEPAC | 2004年 / 5卷 / 3期

关键词：

Botulinum toxin; Cerebral palsy; Costs; Economics; Germany; Paediatrics; Resource use;

D O I：

10.1007/s10198-004-0224-7

中图分类号：

学科分类号：

摘要：

This study was a retrospective survey of the management of a cohort of children with cerebral palsy at Seepark Hospital, Germany, who did (cases; n=107) and did not (controls; n=107) receive botulinum toxin injections. Data on healthcare resource use and clinical outcomes over 12 months were collected from the date cases received their first injection and from the date controls were first admitted into hospital. Botulinum toxin use led to an 85% reduction in the number of children requiring surgery. Additionally, controls used significantly more healthcare resources than cases, particularly hospital bed days (69.2±34.1 vs. 27.5±27.9 days; p <0.0001). The total cost of managing cases and controls was €16,700 and €33,800, respectively. In conclusion, use of botulinum toxin released resources for alternative use during the first year following treatment, without any loss of clinical improvement. However, it is unknown how botulinum toxin affected the need for surgery and associated outcomes in subsequent years.

引用

页码：227 / 235

页数：8

共 39 条

[1]

Albright A.L., Baclofen in treatment of cerebral palsy, J Child Neurol, 11, pp. 77-83, (1996)

[2]

Arroyave Loaiza G., Jarillo Soto E.C., Garfias Garnica M.G., Ribera Ibarra D.B., Uribe Zamarripa J.A., Cost-benefit of the pharmacologic treatment of cerebral palsy with spasticity in Mexico, Rev Esp Salud Publica, 74, pp. 549-559, (2000)

[3]

Bjornson K.F., McLaughlin J.F., The measurement of health-related quality of life (HRQL) in children with cerebral palsy, Eur J Neurol, 8, 5 SUPPL., pp. 183-193, (2001)

[4]

Bodensteiner J.B., The management of cerebral palsy: Subjectivity and a conundrum, J Child Neurol, 11, pp. 75-76, (1996)

[5]

Boyd R.N., Hays R.M., Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: A systematic review, Eur J Neurol, 8, 5 SUPPL., pp. 1-20, (2001)

[6]

Cheng J.C., So W.S., Percutaneous elongation of the Achilles tendon in children with cerebral palsy, Int Orthop, 17, pp. 162-165, (1993)

[7]

Copp E.R., Harris R., Keenan J., Peripheral nerve block and motor point block with phenol in the management of spasticity, Proc R Soc Med, 63, pp. 937-938, (1970)

[8]

Cusick B.D., Splints and casts. Managing foot deformity in children with neuromotor disorders, Phys Ther, 68, pp. 1903-1912, (1988)

[9]

Dabney K.W., Lipton G.E., Miller F., Cerebral palsy, Curr Opin Pediatr, 9, pp. 81-88, (1997)

[10]

Dursun N., Dursun E., Alican D., The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy, Int J Clin Pract, 56, pp. 564-567, (2002)

← 1 2 3 4 →